Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Given the disruption caused by COVID-19, a key question for Q2 was not so much the type of approvals the US regulator granted, but the number. With 11 new drugs approved (Table 1), fears of major disruption to approval timelines were not realized, and at the halfway point of 2020, the FDA has now approved almost double the 13 drugs approved in the first half of 2019. However, data submission for many of these drugs would have occurred before March, and so the full impact of COVID-19 on drug approvals might not be felt until later in the year.